异环磷酰胺与依托泊苷联合治疗复发卵巢癌的临床效果  

Clinical Effect of Combination of Ifosfamide and Etoposide in Treatment of Recurrent Ovarian Cancer

作　　者：刘筠[1] LIU Jun(Department of Medical Affairs,Tianjin Central Hospital of Obstetrics and Gynecology,Tianjin 300100,China)

机构地区：[1]天津市中心妇产科医院科室医政科

出　　处：《医学信息》2019年第13期143-144,共2页Journal of Medical Information

摘　　要：目的探讨异环磷酰胺与依托泊苷联合治疗复发卵巢癌的临床效果。方法选取2018年1月~2019年2月我院收治的复发卵巢癌患者90例,按照随机数字表法分为对照组和观察组,各45例。对照组采用依托泊苷治疗,观察组在对照组基础上联合异环磷酰胺治疗,比较两组化疗后的效果和CA125值的变化。结果观察组CA125、CA125Ⅱ值均低于对照组[(55.62±3.25)U/mlvs(68.42±3.25)U/ml]、[(53.62±2.25)U/mlvs(61.42±5.25)U/ml],差异有统计学意义(P<0.05)。观察组临床总有效率为95.55%,高于对照组的71.11%,差异有统计学意义(P<0.05)。结论异环磷酰胺与依托泊苷联合治疗复发卵巢癌可较快降低肿瘤负荷、减轻相关症状,具有较高的临床应用价值。Objective To investigate the clinical effect of combination of ifosfamide and etoposide in the treatment of recurrent ovarian cancer. Methods 90 patients with recurrent ovarian cancer admitted to our hospital from January 2018 to February 2019 were enrolled. According to the random number table, they were divided into control group and observation group, with 45 cases in each group. The control group was treated with etoposide. The observation group was given combination therapy with ifosfamide and etoposide. The effects of chemotherapy and CA125 values were compared between the two groups. Results The values of CA125 and CA125Ⅱ in the observation group were lower than those in the control group [(55.62±3.25)U/ml vs (68.42±3.25)U/ml ],[(53.62±2.25)U/ml vs (61.42±5.25)U/ml ],the difference was statistically significant (P<0.05). The total effective rate of the observation group was 95.55%, which was higher than that of the control group 71.11%,the difference was statistically significant (P<0.05).Conclusion The combination of ifosfamide and etoposide in the treatment of recurrent ovarian cancer is effective, and the recovery time is short, which has high clinical value.

关 键 词：复发卵巢癌症 异环磷酰胺 依托泊苷 化疗 

分 类 号：R587.1[医药卫生—内分泌]